A single-center observational cohort (n=116; 81% RRMS) receiving ocrelizumab from 2018–2023 enabled longitudinal tracking of IgG, IgA, and IgM across treatment cycles. Serial dosing produced gradual ...

House lawmakers reviewed veterans' health bills focused on mental health, rural access, spinal injury care, and military aviation research. Today, the House Committee on Veterans Affairs subcommittee ...

Legislation delays mandatory digital-only quality reporting for Shared Savings Program ACOs, addressing gaps in EHR/IT infrastructure that disproportionately affect smaller, rural, and independent ...

In this episode, 'Screening, Risk Stratification, and the Multidisciplinary Care Model for MASH,' the hepatologist Nadege Gunn, MD explores the following questions: 1. How would you characterize the ...

Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...

COA’s AI Playbook provides a structured, practice-oriented framework to prioritize AI use cases, align stakeholders, and ...

A $5,000 annual out-of-pocket cap would add catastrophic financial protection to traditional Medicare, harmonizing benefit design with Medicare Advantage and most private insurance coverage.

Indications now include pediatric plaque psoriasis and active PsA starting at age 6, positioning risankizumab as the first US-approved IL-23(p19) inhibitor for <40 kg pediatric patients. Weight-tiered ...

Delgocitinib tripled week-16 treatment success versus placebo (RR 3.17), yielding an absolute 16.9% benefit and NNT of 6. Early separation by week 4 supports adherence, with sustained superiority at ...

Learn how aggressive neuroendocrine carcinoma disrupts daily life—and why rapid treatment, strong caregiver support, and navigation resources matter. In this episode, ‘Current Treatments and Biomarker ...

Wastewater signals suggest increasing SARS-CoV-2 circulation despite low national baselines, reinforcing surveillance as an early indicator rather than a definitive predictor of near-term clinical ...

On National HIV Testing Day, getting tested remains a gateway to prevention and treatment, but improving access alone is not enough. Expanding access to PrEP, PEP, pharmacists, long-acting therapies, ...